Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Acta Pharmacol Sin. 2010 Apr 12;31(5):560–569. doi: 10.1038/aps.2010.31

Figure 4. Attenuation of oxidative damage by trimetazidine(TMZ) treatment.

Figure 4

(A) DCF staining of frozen heart tissue sections from each group suggests that treatment with trimetazidine reduced the ROS generation in db/db mice hearts. DCF staining quantification is expressed as a percentage of relative grayscale value. bP<0.05 compared to C57 group; eP<0.05 compared to db/db group. (B) Malondialdehyde (MDA) levels in heart homogenates from TMZ-treated groups were markedly reduced compared to the db/db group. bP<0.05 compared to the C57 group; eP<0.05 compared to the db/db group.